Guardant Health
About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Employees: 1,779
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
27% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 74
4.64% more ownership
Funds ownership: 98.16% [Q2] → 102.8% (+4.64%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
5% less funds holding
Funds holding: 280 [Q2] → 265 (-15) [Q3]
16% less capital invested
Capital invested by funds: $3.39B [Q2] → $2.84B (-$553M) [Q3]
20% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 54
62% less call options, than puts
Call options by funds: $21.3M | Put options by funds: $56M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Goldman Sachs Matthew Sykes 56% 1-year accuracy 22 / 39 met price target | 10%upside $49 | Buy Maintained | 28 Jan 2025 |
Barclays Luke Sergott 28% 1-year accuracy 13 / 46 met price target | 35%upside $60 | Overweight Initiated | 23 Jan 2025 |
Financial journalist opinion
Based on 12 articles about GH published over the past 30 days









